CYP2C9*13

Cytochrome P450 2C9 (CYP2C9), a member of the CYP2C enzyme subfamily, ranks amongst the most important drug metabolizing enzymes in humans.

Human CYP2C9 has been shown to exhibit genetic polymorphism. In addition to the wild-type protein CYP2C9*1, at least 30 single nucleotide polymorphisms (SNPs) have been reported within the coding region of the CYP2C9 gene producing the variant allozymes. CYP2C9*13 is one of them. It involves a T-to-C transversion at nucleotide position 269 causing a mutation at codon 90, which results in a Leu->Pro substitution. Frequency analysis in 147 unrelated Chinese males indicated approximately 2% of the Chinese population carry the allele. CYP2C9*13 was found in Japanese and Korean, too.

CYP2C9*13 allele was correlated with reduced plasma clearance of drugs that are substrates for CYP2C9.

CYP2C9*13 was found by Si Dayong, Zhou Hui*, Zhang Yifan and Zhong Dafang* in 2004.